Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) will post its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect Arbutus Biopharma to post earnings of ($0.09) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The firm had revenue of $1.73 million during the quarter, compared to analyst estimates of $1.54 million. Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 66.68%. During the same period last year, the company posted ($0.10) EPS. On average, analysts expect Arbutus Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Arbutus Biopharma Stock Up 2.9 %
NASDAQ:ABUS opened at $3.96 on Monday. Arbutus Biopharma has a 52-week low of $1.70 and a 52-week high of $4.72. The stock has a fifty day simple moving average of $4.03 and a 200-day simple moving average of $3.56. The company has a market capitalization of $747.57 million, a PE ratio of -8.80 and a beta of 1.92.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Arbutus Biopharma
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Further Reading
- Five stocks we like better than Arbutus Biopharma
- When to Sell a Stock for Profit or Loss
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- Differences Between Momentum Investing and Long Term Investing
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Why Are These Companies Considered Blue Chips?
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.